Succesful treatment of COVID-19 infection in a child with tracheostomy

Emrah GÜN1(ID)
Edin BOTAN1(ID)
Halil ÖZDEMİR2(ID)
Tanıl KENDİRLİ1(ID)

1 Division of Pediatric Intensive Care, Ankara University
   Faculty of Medicine, Ankara, Turkey
2 Division of Pediatric Infectious Diseases, Ankara University
   Faculty of Medicine, Ankara, Turkey

To the Editor,

We have read the case report presented by Öz et al.(1) with great interest in Tuberk Toraks journal 2020/68 issue. They reported that a case had dyspnea, fever, and increased tracheal secretions due to coronavirus disease 2019 (COVID-19) infection in a 61-year-old male patient with tracheostomy. We followed a child case who had similar features. Our case is going to be told in further. COVID-19 infection is thought to have a milder effect in children than adults (2). COVID-19 infection is generally asymptomatic in most children (3). However, children who have comorbid diseases including congenital heart, lung, and airway diseases, malnutrition, tumors, and etc are sensitive to infection with SARS-CoV-2, and they are prone to severe illness if they get COVID-19 (4).

Here, we report a patient who was a 3-year-old male patient with a diagnosis of hydranencephaly and chronic respiratory failure, followed by a home mechanical ventilator for seven months has fever, respiratory distress. He was transferred to our unit from another center after 2 days of follow-up in the pediatric intensive care unit (PICU). When he was admitted to the PICU, his general condition was moderate to poor. His Glasgow Coma Scale was 12/15. As respiratory care, the patient, followed up in the T-tube in the last few months, was connected to a home-type mechanical ventilator due to increased respiratory distress and...
COVID-19 infection in a child with tracheostomy

increased tracheal secretions for the last 4 days. He was connected to the mechanical ventilator and was monitored in Pressure-Synchronized intermittent mandatory ventilation (P-SIMV) mode. He had fever, vomiting, shortness of breath, increased tracheal secretions for four days. The patient’s body temperature was 38.5°C, blood pressure was 118/75 mm/Hg, heart rate was 186/min, $\text{SpO}_2$ was 95%. On physical examination, there were bilateral rales in the lungs, and he had tachycardia. Arterial blood gas findings were normal. Laboratory results showed WBC was $17.08 \times 10^3/\mu\text{L}$, lymphocyte $6.08 \times 10^3/\mu\text{L}$, Hb, 12.3 g/dl, platelet was $324 \times 10^3/\mu\text{L}$, CRP 198 ng/mL, PCT 19.16 ng/mL, AST, 133 IU/L; ALT, 129 IU/L; troponin T, 7.6 pg/mL (NR: 0-14), NT-pro-BNP, 2072 ng/L, CK-MB 4.82 ng/mL (NR: 0-3.6), LDH 687 U/L, INR of 1.06, aPTT 37.5, PT 12.4, D-dimer of 422 ng/mL (NR: 0-243) fibrinogen 3.22 g/L, (NR: 2-3.93), lipase 203 U/L, amylase 122 U/L. Intravenous fluid therapy and piperacillin-tazobactam were started. His COVID-19 polymerase chain reaction (PCR) test was positive on admission. In the thorax computed tomography (CT) report of the patient, there was a ground glass-like appearance in the lower lobes of both lungs, the upper lobe of the right lung, the lateral middle lobe of the right lung, and the posterior left upper lobe. Dexamethasone and enoxaparin were started for COVID-19 treatment. His echocardiography was normal. He had abdominal distension and increased amylase and lipase in laboratory results. Abdominal ultrasonography of the patient for pancreatitis was normal. On the second day of hospitalization, 

$\text{Pseudomonas aeruginosa}$ was produced in the tracheal aspirate culture. Antibiotherapy was changed to meropenem and amikacin.

On the 14th day of admission, antibiotic therapy was discontinued, and on the 18th day of the admission, the COVID-19 PCR test was resulted as negative. As respiratory care, patient followed up in P-SIMV mode on the mechanical ventilator, was switched to T-tube on the 20th day. He was discharged on the 32nd day.

Various treatments such as interferon, lopinavir, ritonavir, oseltamivir, azithromycin, and hydroxychloroquine have been trialed for COVID-19 infection in children; however, these treatments are not superior to each other (5). Despite all of these uncertainties, mortality rate in children is low. Mortality rate in children due to COVID-19 has been reported as 5 children (0.18%) in a study involving 2843 children (5).

The incidence of lymphopenia in children with COVID-19 is less than in adults, and leukocyte count is usually normal (5). Procalcitonin elevation due to bacterial infection can be seen in these patients (5). Although our patient had severe illness due to COVID-19, lymphocyte count was normal. The leukocyte count and procalcitonin of our patient were high, but it may also be due to concomitant secondary bacterial infection.
In a patient with tracheostomy, the diagnosis of COVID-19 should not be based solely on reverse transcriptase-polymerase chain reaction analysis of nasopharyngeal/ oropharyngeal (NP/OP) swabs, but lower respiratory tract samples should be evaluated if NP/OP swabs are negative (1).

In patients with tracheostomy, frequent aspiration of secretion via the tracheostomy cannula suggests lower respiratory tract infection (1). The presence of secondary bacterial infection should be given broad-spectrum antibiotherapy, because secondary bacterial infections may be observed in these patients and worsen the patient's clinic (1).

As a result, although the mortality rate due to COVID-19 is lower in children compared to adults, COVID-19 may be more severe in children with comorbidities, as in our patient. To the best of our knowledge, our patient is the first patient with tracheostomy who was successfully treated for COVID-19.

REFERENCES
1. Wenzel SE. Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond. Am J Respir Cell Mol Biol 2016; 55: 1-4.
2. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med 2019; 199: 433-45.
3. Samitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med 2017; 23: 48-55.
4. Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int 2019; 68: 158-66.